Recurrent vaginal thrush (vaginal candida). How can this be prevented?
Authors
Fong IW. Bannatyne RM. Wong P.
Institution:
Division of Infectious Diseases, St Michael's Hospital, University of Toronto, 30 Bond Street,Toronto, Ont. M5B 1W8; Canada.
Title:
Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candida (1993-2040b).
Source:
Genitourinary Medicine. Vol 69(1) (pp4-46), 1993.
Abstract:
Objectives:
To determine whether in vitro resistance of Candida albicans to the imidazoles (ketoconazole, clotrimazole and itraconazole) is associated with recurrence of candida vaginitis.
Design:
Candida isolates were collected before, during and after treatment from women with recurrent vaginal candida (>=4 episodes/year), randomised into two prospective studies: (1) 56 women treated with ketoconazole 400 mg/daily for 7 days; (2) 44 women randomised to receive itraconazole 200 mg orally, or clotrimazole 200 mg intravaginally, twice weekly for six months.
Setting:
Women's Candida Clinic at St. Michael's Hospital, a University of Toronto teaching Hospital, Toronto, Ontario, Canada. Main outcome, measures - Isolates of yeasts recovered pre and post treatment were tested for significant changes in 50% inhibitory concentration (IC50). Resistance was defined as a greater than fourfold increase in baseline IC50 of post treatment isolates compared with pretreatment isolates.
Results:
Over 250 strains of C albicans were tested and none showed development of resistance to any of the agents.
Conclusion:
- Recurrence of vaginal candida is not related to the development of drug resistance.
The aim of this web site is to provide a general guide and it is not intended as a substitute for a consultation with an appropriate specialist in respect of individual care and treatment.
